Pages that link to "Q47621653"

The following pages link to Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). (Q47621653):

Displaying 14 items.

• Trastuzumab emtansine: determining its role in management of HER2+ breast cancer (Q47795804) (← links)
• Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells. (Q52729178) (← links)
• Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy (Q59795879) (← links)
• Acquired Resistance to Antibody-Drug Conjugates (Q64069325) (← links)
• Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment (Q64096908) (← links)
• SORLA regulates endosomal trafficking and oncogenic fitness of HER2 (Q64289807) (← links)
• Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (Q89727324) (← links)
• The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 (Q90396696) (← links)
• Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer (Q91992316) (← links)
• Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B (Q92293280) (← links)
• miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments (Q92307006) (← links)
• Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors (Q92571116) (← links)
• Antibody-drug conjugates in gynecologic malignancies (Q92726180) (← links)
• CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity (Q92883016) (← links)